GU Cancers 2019 | Non-clear cell kidney cancer trial updates: CALYPSO and KEYNOTE-427

Tracy Rose

Tracy Rose, MD, of UNC Health Care, Chapel Hill, NC, presents a detailed overview on the Phase II CALYPSO trial (NCT02819596) investigating the use of savolitinib and durvalumab in papillary renal cancer, and the Phase II KEYNOTE-427 study (NCT02853344) looking at the efficacy of pembrolizumab therapy in renal cell carcinoma (RCC). This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video